Conclusion: These results suggest that dronedarone reverses EC dysfunction in hypertensive rats as evidenced by enhanced NO bioavailability and reduced blood pressure levels. How these effects contribute to the benefits of dronedarone in non-permanent AF patients requires further evaluation.